The tumor growth in LLC-circFGFR1 cell recipient xenograft mice showed obvious phenotypic resistance to anti-PD-1 therapy compared with that of the mock cell group, and xenograft mice had a shorter survival time (42). This evidence concerns the gene PDCD1 and neoplasm.